A drug utilisation study of Rifaxamin-α 550mg

Study identification

• EU PAS number:
  EUPAS19445
• Study ID:
  28600
• Official title and acronym:
  A drug utilisation study of Rifaxamin-α 550mg
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A drug utilisation study conducted in CPRD GOLD to understand the dosing, the formulation, the indications and the patient demographics associated with rifaximin-α 550mg tablets across the UK following launch in January 2013.
• Study status:
  Finalised

Research institutions and networks

Institutions

Clinical Practice Research Datalink (CPRD)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 16/12/2014

Actual: 18/12/2014

Study start date

Planned: 21/04/2015

Actual: 06/07/2016

Date of final study report

Planned: 09/07/2015

Actual: 18/01/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Norgine Ltd

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)